New Clinical Trial For Metastatic Prostate Cancer

MEVPRO-1 is a Phase 3 randomized, open-label clinical trial to evaluate an investigational medicine taken orally by tablets called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate (Zytiga®).

MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.

Investigational mevrometostat has the potential to be the first-in-class EZH2 inhibitor for prostate cancer.

MEVPRO-1 is enrolling adult men (18+) who:

• Have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features
• Have evidence of disease progression on or after treatment with at least 12 weeks of abiraterone acetate in the metastatic castration-sensitive prostate (mCSPC) cancer or first-line mCRPC setting
• Have metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan
  
  

Please note: MEVPRO-1 is currently seeking patient participation only. This study is not recruiting new clinical sites at this time. If you or someone you know meets the eligibility criteria above, we encourage you to learn more about patient enrollment.